奥马珠单抗与日本儿童重度哮喘及过敏性合并症中未满足的需求
Omalizumab and unmet needs in severe asthma and allergic comorbidities in Japanese children.
作者信息
Nishima Sankei, Kozawa Masanari, Milligan Ki Lee, Papadopoulos Nikolaos G
机构信息
National Hospital Organization, Fukuoka National Hospital, Fukuoka, Japan.
Medical Division, Novartis Pharma K.K., Tokyo, Japan.
出版信息
Asia Pac Allergy. 2019 Jan 22;9(1):e7. doi: 10.5415/apallergy.2019.9.e7. eCollection 2019 Jan.
Childhood asthma is one condition within a family of allergic diseases, which includes allergic rhinitis, atopic dermatitis, and food allergy, among others. Omalizumab is an anti-IgE antibody therapy that was approved in Japan for children with asthma and added to the Japanese pediatric asthma guidelines in 2017. This review highlights the Japanese clinical perspectives in pediatric allergic asthma, and consideration for allergic comorbidities, and reflects on omalizumab clinical trials in progress to present comprehensive future opportunities.
儿童哮喘是过敏性疾病家族中的一种病症，该家族还包括过敏性鼻炎、特应性皮炎和食物过敏等。奥马珠单抗是一种抗IgE抗体疗法，于2017年在日本获批用于治疗儿童哮喘，并被纳入日本儿科哮喘指南。本综述重点介绍了日本在儿童过敏性哮喘方面的临床观点以及对过敏性合并症的考量，并对正在进行的奥马珠单抗临床试验进行了思考，以展现全面的未来机遇。
Zotero 插件